Tempus AI Sees Unusually High Options Volume (NASDAQ:TEM)

Tempus AI, Inc. (NASDAQ:TEM) was the recipient of some unusual options trading on Wednesday. Stock investors acquired 32,895 call options on the company. This represents an increase of approximately 68% compared to the typical daily volume of 19,625 call options.

Tempus AI Trading Down 3.5%

Shares of TEM opened at $54.42 on Friday. The stock’s 50-day moving average is $50.82 and its two-hundred day moving average is $66.19. The stock has a market cap of $9.73 billion, a PE ratio of -38.60 and a beta of 4.90. Tempus AI has a 12 month low of $39.01 and a 12 month high of $104.32. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. BTIG Research reduced their target price on Tempus AI from $105.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. Needham & Company LLC restated a “buy” rating and set a $75.00 price objective on shares of Tempus AI in a research note on Wednesday, March 11th. Morgan Stanley reduced their price objective on Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. Stifel Nicolaus set a $60.00 price objective on Tempus AI in a research note on Wednesday, February 25th. Finally, Canaccord Genuity Group reduced their price objective on Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, December 22nd. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.36.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Commercial expansion of the co‑branded GenoPredicta whole‑genome sequencing assay with Predicta Biosciences broadens Tempus’ addressable market for hematologic malignancy profiling and MRD monitoring, potentially driving incremental revenue from life‑sciences partners and clinical customers. Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole‑Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring
• Positive Sentiment: Official launch of a new blood‑based cancer test kit and the broader commercial rollout of GenoPredicta generated strong short‑term buying interest (shares jumped on the announcement), signaling investor belief in Tempus’ diagnostics commercialization pathway. Tempus AI (TEM) Unveils Cancer Test Kit, Soars 13.9%
• Positive Sentiment: Analyst activity turned favorable this week — TD Cowen raised Tempus to Buy, Jefferies initiated coverage, and Mizuho maintained a Buy — which can support sentiment and liquidity as institutional interest grows. Tempus AI (NASDAQ:TEM) Raised to “Buy” at TD Cowen Jefferies Financial Group Initiates Coverage on Tempus AI (NASDAQ:TEM) Mizuho Securities Keeps Their Buy Rating on Tempus AI, Inc. Class A (TEM)
• Positive Sentiment: Unusual options activity — a large spike in call buying — indicates some traders were positioning for further upside around the GenoPredicta/news flow. (No link available)
• Neutral Sentiment: Coverage and AACR data are prompting re‑evaluation of Tempus’ precision‑oncology edge; the GenoPredicta dataset may materially help differentiation but remains early for widespread clinical adoption. Could Tempus AI’s GenoPredicta Data Push Quietly Reshape Its Precision Oncology Edge (TEM)?
• Neutral Sentiment: Some investors are reassessing valuation after the GenoPredicta announcements and AACR updates; short‑term sentiment swung sharply higher this week despite a longer‑term share decline. A Look At Tempus AI (TEM) Valuation After GenoPredicta Collaboration And AACR 2026 Cancer Diagnostics Updates
• Negative Sentiment: Execution and valuation risk remain: Tempus shows high volatility (beta ~4.9), a negative P/E, and elevated leverage metrics that make the stock sensitive to short‑term sentiment reversals despite the positive product/clinical news. (Background data)

Insider Transactions at Tempus AI

In related news, CEO Ryan Fukushima sold 9,592 shares of Tempus AI stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $566,407.60. Following the transaction, the chief executive officer owned 694,354 shares in the company, valued at approximately $41,001,603.70. This trade represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Eric P. Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction on Wednesday, January 28th. The shares were sold at an average price of $65.56, for a total value of $10,899,350.00. Following the completion of the transaction, the chief executive officer owned 8,941,533 shares in the company, valued at $586,206,903.48. The trade was a 1.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 563,841 shares of company stock valued at $32,258,311 in the last ninety days. Company insiders own 26.27% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Victory Capital Management Inc. lifted its stake in shares of Tempus AI by 1.5% in the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after acquiring an additional 162 shares in the last quarter. Global Retirement Partners LLC lifted its stake in shares of Tempus AI by 29.5% in the third quarter. Global Retirement Partners LLC now owns 733 shares of the company’s stock worth $59,000 after acquiring an additional 167 shares in the last quarter. US Bancorp DE lifted its stake in shares of Tempus AI by 6.6% in the third quarter. US Bancorp DE now owns 2,848 shares of the company’s stock worth $230,000 after acquiring an additional 176 shares in the last quarter. Legacy Bridge LLC lifted its stake in shares of Tempus AI by 1.6% in the fourth quarter. Legacy Bridge LLC now owns 12,418 shares of the company’s stock worth $733,000 after acquiring an additional 193 shares in the last quarter. Finally, Truist Financial Corp lifted its stake in shares of Tempus AI by 5.8% in the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock worth $209,000 after acquiring an additional 194 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.